

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LIFE HEALTHCARE GROUP LIMITED

蓮和醫療健康集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 928)

(1) DELAY IN PUBLICATION OF THE AUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2022; AND (2) PUBLICATION OF UNAUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2022

This announcement is made by Life Healthcare Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the provisions of inside information under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

Reference is made to the announcement of the Company dated 20 June 2022 in relation to the date of board meeting.

DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2022

The board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Company’s auditing process for the year ended 31 March 2022 (“**FY2022**”) has been adversely affected due to the implementation of the COVID-19 pandemic prevention and control quarantine measures and restrictions in certain cities in mainland China, especially Beijing where the Company’s head office and accounting department are located, including delay in sending and receiving audit confirmations to and from banks, suppliers and customers due to delays in postal services, obtaining financial information of the investee companies, physical inspection of medical equipment and materials, motor vehicles and licences, and suspension of work of the Company’s head office in Beijing due to lockdown measures in mainland China which affected the preparation and gathering process of necessary documents and information required for the audit work. Given that the auditors of the Company (the “**Auditor**”) requires additional time for conducting its audit work, it is anticipated that the Company will be unable to publish the audited annual results of the

Group for FY2022 (the “**2022 Audited Annual Results**”) on or before 30 June 2022 in accordance with Rules 13.49(1) and 13.49(2) of the Listing Rules. The Company expects to publish the 2022 Audited Annual Results upon completion of the audit processes after the 2022 Audited Annual Results have been finalised and agreed by the Auditor as soon as practicable, on or before 31 July 2022. Further announcement(s) will be made by the Company as and when appropriate.

PUBLICATION OF UNAUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2022

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results, it must announce its unaudited financial results based on the information currently available which have yet to be agreed with the auditors. In order to keep the Shareholders and potential investors informed of the Group’s business operation and financial position and to ensure that trading in the shares of the Company is not affected, the Company will publish the preliminary unaudited annual results of the Group for FY2022, which will be reviewed by the audit committee of the Company but have not been agreed with the Auditor, together with the audited comparable figures for the corresponding period in 2021 on 30 June 2022 in accordance with the “Further Guidance on the Joint Statement in relation to Results Announcements in light of the Covid-19 Pandemic” published by the Securities and Futures Commission and The Stock Exchange of Hong Kong Limited on 16 March 2020.

The relevant figures in the unaudited annual results of the Group for FY2022 to be published by the Company on 30 June 2022 may differ from its 2022 Audited Annual Results to be published later. Therefore, Shareholders and potential investors are advised to exercise due caution when dealing in the securities of the Company.

By order of the Board
LIFE HEALTHCARE GROUP LIMITED
Pang Zhen
Executive Director

Hong Kong, 27 June 2022

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Pang Zhen
Mr. Man Wai Lun
Mr. Huang Zhifang

Independent non-executive Directors:

Mr. Liu Xinghua
Mr. Wang Yang
Mr. Chan Man Kiu